Bacterial metabolite indole modulates incretin secretion from intestinal enteroendocrine L cells
The landmark STEP 1 clinical trial showed that this mechanism, combined with lifestyle changes, led to significant weight loss
If nausea, fatigue, or other mild symptoms become unmanageable even with lifestyle changes, your provider may recommend stopping
Works well for many patients, especially those new to GLP-1 therapy
To date, these GLP-1 drugs have been approved to treat three adult populations: individuals with type 2 diabetes, individuals with a body mass index (BMI) of 30 or greater (obesity), and individuals with a BMI between 27 and 30 (overweight) with at least one weight-related health condition, such as cardiovascular disease, high blood pressure, high cholesterol, prior stroke, prior heart attack, and chest pain (angina)
Starting today does not lock you out of future treatments